The taxane limbo: How low can we go? Journal Article
| Authors: | Hudis, C.; Dang, C. |
| Article Title: | The taxane limbo: How low can we go? |
| Keywords: | treatment outcome; leukemia; retrospective studies; clinical trial; doxorubicin; fluorouracil; patient selection; solid tumor; treatment duration; paclitaxel; cancer adjuvant therapy; neoplasm staging; multiple cycle treatment; breast cancer; antineoplastic combined chemotherapy protocols; drug administration schedule; epidermal growth factor receptor 2; tumor markers, biological; antineoplastic agents, phytogenic; editorial; combination chemotherapy; cyclophosphamide; breast neoplasms; docetaxel; drug mechanism; add on therapy; clinical trials, phase iii as topic; dosage schedule comparison; predictive value of tests; epirubicin; microtubule assembly; meta-analysis as topic; receptor, erbb-2; taxoids; optimal drug dose; taxane derivative; estrogen receptor; drug dose regimen; drug sensitivity; infusions, intravenous |
| Journal Title: | JNCI: Journal of the National Cancer Institute |
| Volume: | 100 |
| Issue: | 11 |
| ISSN: | 0027-8874 |
| Publisher: | Oxford University Press |
| Date Published: | 2008-06-04 |
| Start Page: | 761 |
| End Page: | 763 |
| Language: | English |
| DOI: | 10.1093/jnci/djn155 |
| PUBMED: | 18505966 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 17 November 2011" - "CODEN: JNCIA" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
